Research & Ideas
FEBRUARY 25, 2018
1st human application of CRISPR could end sickle cell disease
The breakthrough gene-editing technology CRISPR-Cas9, which was co-discovered by UC Berkeley professor of biochemistry and molecular biology Jennifer Doudna, may soon be applied to humans for the first time to treat sickle cell disease.